Professor of Pediatrics, University Tex Houston
Pediatric Hematology & Oncology
Dr. William K. Hoots, MD
|
|
Give Review
William Hoots practices Pediatric Hematology & Oncology. He researched medicine at University of North Carolina at Chapel Hill School of Medicine. University of North Carolina at Chapel Hill School of Medicine is a one of the best medicals schools. University of North Carolina at Chapel Hill School of Medicine is ranked 22 in research and 2 in primary care medicine He received 1 awards: "Top MD". William K. Hoots is a published doctor. He has 85 papers published. The most current publication "Development of a subdural vein thrombosis following aggressive factor VII replacement for postnatal intracranial haemorrhage in a homozygous factor VII-deficient infant."
Publications
- Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.
- Planning for the future workforce in hematology research.
- National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning: Setting an Agenda Together for the NHLBI of 2025.
- An analysis of the NIH-supported sickle cell disease research portfolio.
- No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation.
- On the value of portfolio diversity in heart, lung, and blood research.
- Von Willebrand factor mutations and new sequence variations identified in healthy controls are more frequent in the African-American population.
- COX-2 expression correlates with survival in patients with osteosarcoma lung metastases.
- Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.
- Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
- Development of a subdural Vein thrombosis following aggressive factor VII replacement for postnatal intracranial haemorrhage in a homozygous factor VII-deficient infant.
- Participation in research: the economic advantages in a haemophilia research population.
- Spontaneous remission of granulocyte colony-stimulating factor-associated leukemia in a child with severe congenital neutropenia.
- Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs.
- Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors.
- The future of plasma-derived clotting factor concentrates.
- The effect of plasma human immunodeficiency virus RNA and CD4(+) T lymphocytes on growth measurements of hemophilic boys and adolescents.
- Relation between HIV-1 and hepatitis C viral load in patients with hemophilia.
- Response to measles, mumps, and rubella revaccination among HIV-positive and HIV-negative children and adolescents with hemophilia. Hemophilia Growth and Development S...
- History of plasma-product safety.
- Safety issues affecting hemophilia products.
- The Food and Drug Administration's perspective on plasma safety.
- Viral reduction techniques: types and purpose.
- The impact of Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease on plasma safety.
- Severe osteopenia in a young boy with Kostmann's congenital neutropenia treated with granulocyte colony-stimulating factor: suggested therapeutic approach.
- Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.
- Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe throm...
- The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.
- Non-overt disseminated intravascular coagulation: definition and pathophysiological implications.
- Comprehensive care for hemophilia and related inherited bleeding disorders: why it matters.
- Knowledge, attitudes, and behaviors of youths in the US hemophilia population: results of a national survey.
- Evidence for the benefits of prophylaxis in the management of hemophilia A.
- Counteracting the effects of anticoagulants and antiplatelet agents during neurosurgical emergencies.
- Pathogenesis of hemophilic arthropathy.
- Challenges in the therapeutic use of a "so-called" universal hemostatic agent: recombinant factor VIIa.
- Arthropathy in inhibitor patients: differences in the joint status.
- IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection.
- Advances in hemophilia: experimental aspects and therapy.
- Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.
- Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus.
- The registry and surveillance in hemoglobinopathies: improving the lives of individuals with hemoglobinopathies.
- Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
- Delays in maturation among adolescents with hemophilia and a history of inhibitors.
- Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature.
- Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major sur...
- Thrombocytosis in the NICU.
- Linking the world with training and research for improving haemophilia care.
- Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors.
- Pathogenesis of haemophilic synovitis: clinical aspects.
- Pathogenesis of haemophilic synovitis: experimental studies on blood-induced joint damage.
- Human plasma-derived concentrates: preventing Thrombosis and controlling haemorrhage.
- The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report.
- International workshop on immune tolerance induction: consensus recommendations.
- Unresolved issues in diagnosis and management of inherited bleeding disorders in the perinatal period: a White Paper of the Perinatal Task Force of the Medical and Sci...
- Commentary: ''switching between full-length and B-domain deleted factor VIII and the risk of inhibitors''.
- The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis...
- Inhibitor treatment in haemophilias A and B: summary Statement for the 2006 international consensus conference.
- Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors.
- Urgent inhibitor issues: targets for expanded research.
- High-titer inhibitor development in hemophilia A: lack of product specificity.
- Consensus recommendations for use of central venous access devices in haemophilia.
- Hemorrhage following hematopoetic stem cell transplantation--which arrows belong in the quiver?
- Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B.
- Porphyria cutanea tarda in association with human immunodeficiency virus infection in a hemophiliac.
- Comprehensive care for patients with hemophilia: an expanded role in reducing risk for human immunodeficiency virus.
- Disseminated intravascular coagulation and hemorrhage in hemophilia B following elective surgery.
- Stimulation of myelopoiesis in a patient with congenital neutropenia: biology and nature of response to recombinant human granulocyte-macrophage colony-stimulating fac...
- Platelet dysfunction associated with Wilms tumor and hyaluronic acid.
- Activated prothrombin complex concentrates in the management of the hemophiliac with Factor VIII inhibitor: case report.
- "Look back" program for blood product recipients: experience with the pediatric population in Houston, Texas.
- Human immunodeficiency virus-associated vitiligo: expression of autoimmunity with immunodeficiency?
- Aggressive combination therapy in the successful management of life-threatening intracranial hemorrhage in a patient with idiopathic thrombocytopenic purpura.
- Clinicopathological correlations of disseminated intravascular coagulation in patients with head injury.
- Treatment of murine testicular leukemia.
- A naturally occurring antibody that inhibits fibrin polymerization.
- Bruising and recurrent bleeding in children.
- Medical necessity--a threat to treatment of chronic disease.
- A multicenter study of viral hepatitis in a United States hemophilic population.
- Hemophilia growth and development study. Design, methods, and entry data.
- AIDS-associated non-Hodgkin's lymphomas as primary and secondary AIDS diagnoses in hemophiliacs. Hemophilia Malignancy Study Group.
- Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer.
- Experience with antithrombin concentrates in neurotrauma patients.
- PFA-100 system: a new method for assessment of platelet dysfunction.
- Are there clinical and laboratory predictors of 5-year mortality in HIV-infected children and adolescents with hemophilia?
Schools
University Of North Carolina Chapel Hill School Of Medicine
Chldns Med Center
University Nc Med School
Conditions Treated
- Deep Vein Thrombosis (DVT)
- Hypercoagulable State
Doctors Specialties
- Pediatric Hematology
- Oncology
Accepted Insurances
Awards
- Top MD
Education
-
University of North Carolina Hospitals -
University of North Carolina at Chapel Hill School of Medicine
Helpful Reviews
Similar Doctors
|
Dr. William L. Nix, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Karen R. Rabin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cesar A. Nunez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hari Sankaran, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Swati Naik, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Murali Chintagumpala, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Raja H. Ataya, MD
This Doctor is OpenDoctor Recommended.
|